• ER-Targeted Peptide Self-Assembly for Cancer Cell Fate Modul

  2026-06-29

  This article examines a study that advances enzyme-instructed self-assembly (EISA) by engineering endoplasmic reticulum (ER)-targeting peptides for selective modulation of cancer cell fate. The approach leverages elevated alkaline phosphatase (ALP) in cancer cells to induce ER-localized assemblies, triggering ER stress and enhancing cell death pathways, with implications for more efficient, organelle-targeted cancer therapies.

• LY2228820: Selective p38 MAP Kinase Inhibitor for Research

  2026-06-29

  LY2228820 is a selective, ATP-competitive p38 MAP kinase inhibitor with nanomolar potency for p38α/β isoforms. It enables precise modulation of inflammation and cell proliferation pathways in anti-inflammatory and cancer research, as demonstrated by multiomics and translational studies.

• Tomivosertib Suppresses Ectopic Activity in Human DRG Neuron

  2026-06-28

  The referenced study provides the first direct evidence that tomivosertib, a MNK inhibitor, rapidly and reversibly reduces spontaneous ectopic activity in human dorsal root ganglion neurons from patients with radiculopathy. These findings highlight a potential translational pathway for targeting neuropathic pain at its peripheral neuronal source.

• Unraveling sEH/Nrf2 Mechanisms: BPN-19186 in Translational R

  2026-06-27

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) is reshaping biochemical research on osteoclastogenesis and redox signaling. This article bridges mechanistic insight, protocol recommendations, and strategic guidance for translational researchers seeking to harness APExBIO's high-purity inhibitor in signaling pathway and enzyme inhibition studies, with a focus on osteoporosis and beyond.

• Auranofin and the Future of Redox-Driven Cancer Research

  2026-06-26

  This article explores how Auranofin, a gold-based thioredoxin reductase inhibitor, is redefining translational oncology by targeting redox homeostasis, apoptosis, and radiosensitivity. Going beyond conventional product narratives, we integrate mechanistic insights, recent literature, and actionable guidance—positioning Auranofin as a strategic tool for researchers tackling metabolic reprogramming and therapy resistance in hepatocellular carcinoma and other aggressive cancers.

• ECL Western Blotting Substrate: Protocol Guidance and Best U

  2026-06-26

  ECL Western Blotting Substrate (SKU K2187) addresses the need for sensitive, nonradioactive detection of horseradish peroxidase (HRP) in chemiluminescent Western blot assays. It should be used exclusively for HRP-based immunoblotting and is not suitable for fluorescent or radioisotopic detection protocols.

• Ivermectin in Parasitology Research: Mechanisms, Integrity,

  2026-06-25

  Explore how Ivermectin, a broad-spectrum anti-parasitic, advances parasitology research with unmatched purity and mechanism-driven efficacy. This article uniquely bridges rigorous compound handling with new findings from oncology, offering researchers a deeper perspective.

• GDC-0068 (RG7440): Selective Pan-AKT Inhibition in PI3K/Akt/

  2026-06-25

  GDC-0068 (RG7440) is a potent, ATP-competitive pan-AKT inhibitor designed for selective targeting of Akt1, Akt2, and Akt3. It is widely used to dissect PI3K/Akt/mTOR pathway dynamics and tumor cell fate. APExBIO's GDC-0068 offers robust selectivity, high solubility in DMSO and ethanol, and validated efficacy in multiple cancer models.

• Patient-Derived 3D Spheroids Advance Prostate Cancer Modelin

  2026-06-24

  This study presents a robust protocol for generating patient-derived three-dimensional (3D) spheroid cultures from radical prostatectomy specimens, providing a physiologically relevant in vitro model for organ-confined prostate cancer. The findings highlight the model's cellular fidelity and its practical utility for drug-response studies, holding promise for more translationally relevant prostate cancer research.

• Metal-Ion Chelating L-Phe Nanostructures Boost ICB in Breast

  2026-06-23

  This study reveals that metal-ion-chelating L-phenylalanine nanostructures, when combined with short-term starvation, can remodel the tumor microenvironment and enhance the efficacy of immune checkpoint blockade in breast cancer. The work elucidates a novel mechanism of dendritic cell activation through ion channel modulation, offering new strategies for overcoming immunotherapy resistance in solid tumors.

• InstaBlue Protein Stain Solution for Rapid Gel Visualization

  2026-06-23

  InstaBlue Protein Stain Solution enables fast, sensitive protein detection in polyacrylamide gels without the need for fixation, washing, or hazardous solvents. It is best used where immediate visualization and downstream mass spectrometry compatibility are required, but may not be appropriate for workflows demanding in-gel renaturation or traditional Coomassie protocols.

• Ranolazine: Protocols and Innovations for Cardiac Ischemia R

  2026-06-22

  Ranolazine stands out as an anti-ischemic agent, shifting cardiac and hepatic metabolism to enhance cellular resilience under ischemic stress. This article delivers protocol enhancements, troubleshooting strategies, and translational insights that empower advanced cardiac ischemia and metabolic research workflows.

• Machine Learning Unlocks Novel Senolytics for Senescence Res

  2026-06-22

  The referenced study demonstrates how machine learning, trained on heterogeneous published data, enabled the identification and validation of new senolytic compounds targeting cellular senescence. This approach offers cost-effective, data-driven strategies for accelerating drug discovery in cancer and aging-related research.

• Moxidectin: Macrocyclic Lactone Anthelmintic for Dual Applic

  2026-06-21

  Moxidectin is a macrocyclic lactone anthelmintic with established efficacy in veterinary parasitic worm control and newly documented synergy with polyene antifungals against Candida albicans. This review details its mechanism, benchmarks, and translational potential, with evidence-backed protocol guidance.

• Merimepodib (VX-497): Expanding Therapeutic Frontiers via Ho

  2026-06-20

  Discover how Merimepodib (VX-497) targets host IMPDH to combat viral infections and modulate immune responses. This deep-dive explores recent breakthroughs, advanced applications, and practical assay insights beyond standard protocols.

451 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page